原発不明がん

出版社: 医学と看護社
著者:
発行日: 2021-03-20
分野: 臨床医学:一般  >  癌/腫瘍一般
ISBN: 9784909888211
電子書籍版: 2021-03-20 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:約3営業日

3,520 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,520 円(税込)

商品紹介

原発不明がんの診断・治療と看護に携わる方々に最適なテキスト誕生!
原発不明がんについて、患者さんにどのように説明するのが良いのか。どのように取り扱えば良いのか。診断や治療はどうするのか。本書はその疑問にお応えすべく、原発不明がんの疾患概念、その原因、疫学、病理診断、臨床像、診断、治療、治療方針といった原発不明がんの臨床を中心にまとめたテキストです。
がんの診療にあたる医師や研修医はもちろん、たくさんの専門用語について脚註でわかりやすく解説し、看護師、薬剤師などコメディカルの方々にも最適な教科書となっています。

目次

  • 第1章 原発不明がんとは、その疾患概念
    第2章 原発不明がんの原因
     1.原発巣が成長する早い段階で転移を起こす、さらに原発巣が消退
     2.潜在的ながんの発生素地が原発巣以外にも存在
     3.検査で検索困難な部位に原発巣が存在
     4.診断時に広い範囲に病変が広がり、原発巣を同定することが困難
    第3章 原発不明がんの疫学
    第4章 原発不明がんの病理診断
    第5章 原発不明がんの臨床像
    A.特定の治療を有するサブグループの臨床像
     1.腺癌
     2.扁平上皮癌
     3.神経内分泌腫瘍
     4.単発性、切除可能な小病変のみ
    第6章 原発不明がんの診断
    第7章 原発不明がんの治療
    A.特定の治療を有するサブグループに対する治療
     1.腺癌
     2.低・未分化癌
     3.扁平上皮癌
     4.神経内分泌腫瘍
     5.単発性、切除可能な小病変のみを有する症例
    B.特定の治療を有しない原発不明がんに対する治療
     1.いわゆる“経験的”化学療法
     2.特定の治療を有しない原発不明がんにおける推定される原発巣に準じた治療
    第8章 原発不明がんに対する治療方針
    第9章 終わりに

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

引用文献

P.58 掲載の参考文献
1) Vgolkov Aら. Section III 19 Invasion, metastases, and tumor dormancy. Cancer Biology (Pezella Fら編), Oxford, United Kingdom, pp270-282, 2019
2) 日本がんサポーティブケア学会編. がん悪液質ハンドブック, 2019
3) Union for International Cancer Control (by Brierley JDら編). Introduction. pp1-15, 8th ed, John Wiley & Sons, Oxford, 2017
4) Pavlidis Nら. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39 : 1990-2005, 2003
5) Alshareeda ATら. Cancer of unknown primary site : real entity or misdiagnosed disease?, J Cancer 11 : 3919-3931, 2020
6) Kramer Aら. CUP syndrome : molecular pathogenesis and biology. Pathologie 30 : 117-124, 2009
7) Bonnie LB, Ulbright TM. Spontaneous regression of testicular germ cell tumors : an analysis of 42 cases. Am J Srug Pathol 30 : 858-865, 2006
8) De Waal ACら. Melanoma of unknown primary origin : a population-based study in the Netherlands. Eur J Cancer 49 : 676-683, 2013
9) Oosterhuis JW, Stoop Hら. Why human extragonadal germ cell tumors occur in the midline of the body : old concepts, new perspectives. Int J Androl 30 : 256-264, 2007
10) Mandai Mら. Ovarian cancer in endometriosis : molecular biology, pathology, and clinical management. Int J Clin Oncol 14 : 383-391, 2009
11) Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet 379 : 1428-1435, 2012
12) Urban Dら. Cancer of unknown primary : a population-based analysis of temporal change and socioeconomic disparities. Br J Cancer 109 : 1318-1324, 2013
13) Rassy E, Pavlidis N. The currently declining incidence of cancer of unknown primary. Cancer Epidemiol 61 : 139-141, 2019
14) 「がんの統計」編集委員会編. がんの統計 '19, 69, 公益財団法人 がん研究振興財団, 2020
15) Hess KRら. Classification and regression tree analysis of 1,000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5 : 3403-3410, 1999
16) Riihimaki Mら. Comparison of survival of patients with metastases from known versus unknown primaries : survival in metastatic cancer. BMC Cancer 13 : 36, 2013
17) Kim CSら. Survival outcome differences based on treatments used and knowledge of the primary tumour site for patients with cancer of unknown and known primary in Ontario. Curr Oncol 25 : 307-316, 2018
18) Greco FAら. Chapter 137. Cancer of unknown primary site. Principles and Practice of Oncology, 9th ed (DeVitaら編), Liipincott-Raven, Philadelphia, pp2033-2051, 2019
19) Culine Sら. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20 : 4679-4683, 2002
20) Pentheroudakis Gら. Switching benchmarks in cancer of unknown primary : from autopsy to microarray. Eur J Cancer 43 : 2026-2036, 2007
21) Hainsworth JDら. Drug Therapy : treatment of patients with cancer of an unknown primary site. N Engl J Med 329 : 257-263, 1993
22) Rassy E, Pavlidis N. Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nat Rev Clin Oncol 17 : 541-554, 2020
23) Selves Jら. Immunohistochemistry for diagnosis of metastatic carcinomas of unknown primary site. Cancers (Basel) 10 : 108, 2018 ; doi : 10.3390
24) Kandalaft PL, Grown AM. Practical applications in immunohistochemistry. Carcinomas of unknown primary site. Arch Pathol Lab med 140 : 508-523, 2016
25) Riihimaki Mら. Clinical landscape of cancer metastases. Cancer Med 7 : 5534-5542, 2018
26) Hyphantis Tら. Psychiatric manifestations, personality traits and health-related quality of life in cancer of unknown primary site. Psychooncol 22 : 2009-2015, 2013
27) Fizazi Kら. Cancers of unknown primary site : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol v133-138, 2015 (Suppl 5)
28) Merson Mら. Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer 70 : 504-508, 1992
29) De Bresser Jら. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis : a systemic review. Eur J Surg Oncol 36 : 114-119, 2010
30) Bloss JDら. Extraovarian peritoneal serous papillary carcinoma : a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 50 : 347-351, 1993
31) Black Dら. 41 Fallopian tube and peritoneal cancers. Section 7 : Gynecological cancers. Textbook of uncommon cancer (Raghavan Dら編), 4th ed, pp582-590, John Wiley & Sons Ltd, England, 2017
32) Stephen Aら. Chapter 104. Ovarian Cancer, Fallopian tube carcinoma, and peritoneal carcinoma. Principles and Practice of Oncology, 9th ed (DeVitaら編), Liipincott-Raven, Philadelphia, pp1368-1391, 2019
33) Inoue Mら. Specific sites of metastases in invasive lobular carcinoma : a retrospective cohort study of metastatic breast cancer. Breast Cancer 24 : 667-672, 2017
34) Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12 : 6243s-6249s, 2006
35) Piccioli Aら. Bone metastases of unknown origin : epidemiology and principle of management. J Orthopaed Traumatol 16 : 81-86, 2015
36) Leung AKら. The clinical course of patients with prostate-specific antigen > 100 ng/ml : insight into a potential population for targeted prostate-specific antigen screening. Urology 117 : 101-107, 2018
37) Varadhachary GRら. Carcinoma of unknown primary with gastrointestinal profile : immunohistochemistry and survival data for this favorable subset. Int J Clin Oncol 19 : 479-484, 2014
38) Solon JGら. An 18 year population-based study on site of origin and outcome of patients with peritoneal malignancy in Ireland. Eur J Surg Oncol 43 : 1924-1931, 2017
39) Gopalan Aら. Urachal carcinoma : a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol 33 : 659-668, 2009
40) Riva Gら. Urachal carcinoma : from gross specimen to morphologic, immunohistochemical, and molecular analysis. Virchows Arch 474 : 13-20, 2019
41) Szarvas Tら. Clinical, prognostic, and therapeutic aspects of urachal carcinoma-a comprehensive review with meta-analysis of 1,010 cases. Urol Oncol 34 : 388-398, 2016
42) De Ridder Jら. Incidence and origin of histologically confirmed liver metastases : an explorative case-study of 23,154 patients. Oncotarget 7 : 55368-55376, 2016
43) Jesse RHら. Cervical node metastases : unknown primary cancer. Cancer 31 : 854-859, 1973
44) Jereczek-Fossa BAら. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. Cancer Treat Rev 30 : 153-164, 2004
45) Rusthoven KEら. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 101 : 2641-2649, 2004
46) Begum Sら. Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 13 : 1186-1191, 2007
47) Lee WYら. Epstein-Barr virus DNA detection in neck metastases by in-situ hybridization in fine-needle aspiration cytologic studies : an aid for differentiating the primary site. Head Neck 22 : 336-340, 2000
48) Union for International Cancer Control (by Brierley JDら編). Head and Neck Tumours. pp17-56, 8th ed, John Wiley & Sons, Oxford, 2017
49) Zaren HAら. Inguinal node metastases. Cancer 41 : 919-923, 1978
50) Kim JYら. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol 29 : 11-16, 2017
51) Yao JCら. One hundred years after "carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26 : 3063-3072, 2008
52) Hendifar AEら. Current practices and novel techniques in the diagnosis and management of neuroendocrine tumors of unknown primary. Pancreas 48 : 1111-1118, 2019
53) Bergsland EK, Nakamura EK. Neuroendocrine tumors of unknown primary : is the primary site really not known? JAMA Surg 149 : 889-890, 2014
54) Deroose CMら. Molecular imaging of gastroenteropancreatic neuroendocrine tumors : current status and future directions. J Nucl Med 57 : 1949-1956, 2016
55) Dasari Aら. Comparative study of lung and extrapulmonary poorly differenciated neuroendocrine carcinomas : a SEER database analysis of 162,983 cases. Cancer 124 : 807-815, 2018
56) Zuur CLら. Diagnosis and treatment of isolated neck metastases of adenocarcinomas. Eur J Surg Oncol 28 : 147-152, 2002
57) Abbruzzese BJLら. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 13 : 2094-2103, 1995
58) NCCN. Occult primary (Cancer of unknown primary [CUP]) version 3.2020 https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf
59) Rusthoven KEら. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 101 : 2641-2649, 2004
60) Seve Pら. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 109 : 292-299, 2007
61) Burglin SAら. 18F-FDG PET/CT for detection of primary tumor in adults with extracervical metastases from cancer of unknown primary : a systemic review and meta-analysis. Medicine 96 : e6713, 2017
62) Molina Rら. Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. Tumor Biol 33 : 463-474, 2012
63) Farag SSら. Delay by internists in obtaining diagnostic biopsies in patients with suspected cancer. Ann Intern Med 116 : 473-478, 1992
64) 日本臨床腫瘍学会 (編). 原発不明がん診療ガイドライン 改訂第2版. pp29-30, 南江堂, 東京, 2018
65) NICE. Metastatic malignant disease of unknown primary origin in adults : diagnosis and management, 2010. https://www.nice.org.uk/guidance/cg104/chapter/1-guidance
66) Bochtler Tら. Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. Int J Cancer 145 : 2963-2973, 2019
67) Sato Jら. The incidence of non-maligant diseases among patients with suspected carcinoma of unknown primary site. Intern Med 58 : 1423-1428, 2019
68) Greco FAら. Molecular profiling diagnosis in unknown primary cancer : accuracy and ability to complement standard pathology. J Natl Cancer Inst 105 : 782-790, 2013
69) Merson Mら. Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer 70 : 504-508, 1992
70) Varadarajan Rら. Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology 71 : 456-459, 2006
71) Galimbertiら. Clinical experience with axillary presentation breast cancer. Breast Cancer Res Treat 88 : 43-47, 2004
72) Bloss JDら. Extraovarian peritoneal serous papillary carcinoma : a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study. Gynecol Oncol 89 : 148-154, 2003
73) Gentile PSら. Disseminated prostatic carcinoma simulating primary lung cancer Indications for immunodiagnostic studies. Cancer 62 : 711-715, 1988
74) Varadhachary GRら. Carcinoma of unknown primary with gastrointestinal profile : immunohistochemistry and survival data for this favorable subset. Int J Clin Oncol 19 : 479-484, 2014
75) Thomassen Iら. Population-based incidence, treatment and survival of patients with peritoneal metastases of unknown origin. Eur J Cancer 50 : 50-56, 2014
76) Richardson RLら. The unrecognized extragonadal germ cell cancer syndrome. Ann Intern Med 94 : 181-189, 1981
77) Bauer DEら. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 18 : 5773-5779, 2012
78) Patel RSら. Squamous cell carcinoma from an unknown head and neck primary site : a "selective treatment" approach. Arch Otolaryngol Head Neck Surg 133 : 1282-1287, 2007
79) Aslani Mら. Metastatic carcinoma to the cervical nodes from an unknown head and neck primary site : Is there a need for neck dissection? Head Neck 29 : 585-590, 2007
80) Strojan Pら. Squamous cell carcinoma of unknown primary tumor metastatic to neck nodes : role of elective irradiation. Eur Arch Otorhinolaryngol 273 : 4561-4569, 2016
81) Lou Jら. Squamous cell carcinoma of cervical lymph nodes from an unknown primary site : the impact of neck dissection. J Cancer Res Ther 11 : c161-c167, 2015 (suppl 2)
82) Shehadeh NJら. Benefit of postoperative chemoradiotherapy for patients with unknown primary squamous cell carcinoma of the head and neck. Head Neck 28 : 1090-1098, 2006
83) Eldeeb Hら. Squamous cell carcinoma metastatic to cervical lymph nodes from unknown primary origin : the impact of chemoradiotherapy. Chin J Cancer 31 : 484-490, 2012
84) Guarischi Aら. Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases. Cancer 59 : 572-577, 1987
85) Joseph Kら. Carcinoma of unknown primary in the inguinal lymph node region of squamous cell origin : A case series. Pract Radiat Oncol 4 : 404-408, 2014
86) Kvols LKら. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315 : 663-666, 1986
87) Rinke Aら. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group. J Clin Oncol 27 : 4656-4663, 2009
88) Caplin MEら. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371 : 224-233, 2014
89) Yao JCら. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4) : a randomised, placebo-controlled, phase 3 study. Lancet 387 : 968-977, 2016
90) Raymond Eら. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364 : 501-513, 2011
91) Wong MHら. Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). PLoS One 11 : e0158140, 2016
92) Mitry Eら. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81 : 1351-1355, 1999
93) Hainsworth JDら. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma : A Minnie Pearl Cancer Research Network Study. J Clin Oncol 24 : 3548-3554, 2006
94) Nakano Kら. Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas. Jpn J Clin Oncol 42 : 697-703, 2012
95) Nguyen LNら. Brain metastases as the only manifestation of an undetected primary tumor. Cancer 83 : 2181-2184, 1998
96) Hainsworth JDら. Carcinoma of unknown primary site : treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 15 : 2385-2393, 1997
97) Greco FAら. Carcinoma of unknown primary site. Long term follow-up after treatment with paclitaxel, carboplatin, and etoposide. Cancer 89 : 2655-2600, 2000
98) Briasoulis Eら. Carboplatin plus paclitaxel in unknown primary carcinoma : a phase II study. The Hellenic Cooperative Oncology Group Study. J Clin Oncol 18 : 3101-3117, 2000
99) Greco FAら. Carcinoma of unknown primary site : phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 11 : 211-215, 2000
100) Greco FAら. Gemcitabine, carboplatin and paclitaxel for patients with carcinoma of unknown primary site : a Minnie Pearl Cancer Research Network study. J Clin Oncol 20 : 1651-1656, 2002
101) Balana Cら. A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site. Ann Oncol 14 : 1425-1429, 2003
102) Greco FAら. Carcinoma of unknown primary site : sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan : A Minnie Pearl Cancer Research Network Phase II trial. Oncologist 9 : 644-652, 2004
103) Pittman KBら. Gemcitabine and carboplatin in carcinoma of unknown primary site : a phase 2 Adelaide Cancer Trials and Education Collaborative. Br J Cancer 95 : 1309-1313, 2006
104) Schneider BJら. Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. Cancer 110 : 770-775, 2007
105) Pentheroudakis Gら. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary : a multicentre Hellenic Cooperative Oncology Group phase II study. Acta Oncol 47 : 1148-1155, 2008
106) Briasoulis Eら. Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary : a hellenic cooperative oncology group study. Cancer Chemother Pharmacol 62 : 277-284, 2008
107) Yonemori Kら. Irinotecan plus carboplatin for patients with carcinoma of unknown primary site. Br J Cancer 100 : 50-55, 2009
108) Moller AKら. Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study. Acta Oncol 49 : 423-430, 2010
109) Carlson Hら. A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary. Int J Clin Oncol 18 : 226-231, 2013
110) Demirci Uら. Docetaxel and cisplatin in first line treatment of patients with unknown primary cancer : a multicenter study of the Anatolian Society of Medical Oncology. Pac J Cancer Prev 15 : 1581-1584, 2014
111) Dowell JEら. A randomized Phase II trial in patients with carcinoma of an unknown primary site. Cancer 91 : 592-597, 2001
112) Culine Sら. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site : results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 21 : 3479-3482, 2003
113) Palmeri Sら. Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study. Cancer 107 : 2898-2905, 2006
114) Huebner Gら. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adenoor undifferentiated carcinoma of unknown primary : a randomised prospective phase II trial. Br J Cancer 100 : 44-49, 2009
115) Hainsworth JDら. Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site : a randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J 16 : 70-75, 2010
116) Lee Jら. Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary : a systematic review and meta-analysis. Br J Cancer 108 : 39-48, 2013
117) Hainswoth JDら. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site : results of a 12-year experience. J Clin Oncol 10 : 912-922, 1992
118) Greco FAら. Molecular profiling in unknown primary cancer : accuracy of tissue of origin prediction. Oncologist 15 : 500-506, 2010
119) Yoon HHら. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus : NCCTG N0871 (alliance). Ann Oncol 27 : 339-344, 2016
120) Varadhachary GRら. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 17 : 4063-4070, 2011
121) Handrof CRら. A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. Am J Surg Pathol 37 : 1067-1075, 2013
122) Hainsworth JDら. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site : a prospective trial of the Sarah Cannon research institute. J Clin Oncol 31 : 217-223, 2013
123) Moran Sら. Epigenetic profiling to classify cancer of unknown primary : a multicentre, retrospective analysis. Lancet Oncol 17 : 1386-1395, 2016
124) Hayashi Hら. Site-specific targeted therapy based on molecular profiling by next-generation sequencing for cancer of unknown primary site a nonrandomized phase 2 clinical trial. JAMA Oncol 6 : 1-9, 2020
125) Hayashi Hら. Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site. J Clin Oncol 37 : 570-579, 2019
126) Fizazi Kら. Phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of ana unknown primary (CUP) site (GEFCAPI 04 trial) [abstr LBA15_PR]. Ann Oncol 30 (suppl. 5) : v851-v934, 2019
127) Hasegawa Hら. Site-specific chemotherapy based on predicted primary site by pathological profile for carcinoma of unknown primary site. Clin Oncol 30 : 667-673, 2018
128) Rassy Eら. New rising entities in cancer of unknown primary : Is there a real therapeutic benefit?. Critic Rev Oncol Hematol 147 : 102882, 2020
129) Gatalica Zら. Comprehensive analysis of cancers of unknown primaryfor the biomarkers of response to immune checkpointblockade therapy. Eur J Cancer 94 : 179-186, 2018
130) 「診療報酬の算定方法の一部改正に伴う実施上の留意事項について」厚生労働省保険局医療課, 令和元年5月31日 (https://ajhc.or.jp/siryo/20190601-21.pdf)
131) Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med 371 : 757-765, 2014
132) Holmes Fら. Metastatic cancer of unknown primary site. Cancer 26 : 816-820, 1970
133) Conway AMら. Molecular characterization and liquid biomarkers in carcinoma of unknown primary (CUP) : taking the 'U' out of 'CUP'. Br J Cancer 120 : 141-153, 2019

最近チェックした商品履歴

Loading...